This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
home:pathogenesis:vitamind:longterm [02.13.2019] – [Notes and comments] sallieq | home:pathogenesis:vitamind:longterm [06.11.2019] – [Also] sallieq | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Immunosuppression and insufficient followup in vitamin D studies ====== | ====== Immunosuppression and insufficient followup in vitamin D studies ====== | ||
+ | < | ||
+ | |||
+ | |||
One of the abiding weaknesses of studies on the effects of vitamin D on health is that researchers simply do not follow subjects consuming the secosteroid for a sufficient period of time. Instead, they tend to track subjects over the course of weeks, months, or one or two years, during the period of time when study participants are usually feeling the palliative effects of the steroid. | One of the abiding weaknesses of studies on the effects of vitamin D on health is that researchers simply do not follow subjects consuming the secosteroid for a sufficient period of time. Instead, they tend to track subjects over the course of weeks, months, or one or two years, during the period of time when study participants are usually feeling the palliative effects of the steroid. | ||
Line 73: | Line 76: | ||
- | [[https:// | + | view [[https:// |
+ | |||
+ | ===== Furthermore ===== | ||
+ | |||
+ | Two recent publications challenge the belief that 25(OH)D levels greater than 30 ng/mL are optimal for bone health. In a randomized, placebo-controlled trial, high-dose, once-yearly vitamin D therapy increased the incidence of fractures and falls. The second study reported that high-dose vitamin D did not reduce levels of parathyroid hormone or bone resorption among adults with 25(OH)D levels less than 32 ng/mL at baseline. It is time to question whether serum 25(OH)D levels of 30 ng/mL or greater are necessary for all individuals. (({{pubmed> | ||
+ | |||
+ | |||
+ | |||
+ | Blood vitamin D levels were associated with a risk of metabolic syndrome in cross-sectional studies but not in longitudinal studies. (({{pubmed> | ||
+ | |||
+ | Evidence does not support the use of vitamin D supplementation for the prevention of cancer, respiratory infections or rheumatoid arthritis. Similarly, evidence does not support vitamin D supplementation for the treatment of multiple sclerosis and rheumatoid arthritis or for improving depression/ | ||
+ | |||
+ | New evidence indicates that both high and low 25(OH)D levels may be associated with increased health risks.(({{pubmed> | ||
+ | |||
+ | Despite a few hundred systematic reviews and meta-analyses, | ||
+ | |||
+ | |||
+ | |||